載入中
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
前收盤價
US$2.85
+US$0.08 · +2.89%
盤前
US$2.887
+US$0.037 · +1.30%
10月12日 上午6:34 ET
盤中時間採用ET。市場資料可能有所延遲。
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
日內區間
目前US$2.85
52週區間
目前US$2.85
盤中時間採用ET。市場資料可能有所延遲。
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
日內區間
目前US$2.85
52週區間
目前US$2.85
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.18萬 USD | — | — | 23.33萬 USD | 63.8萬 USD |
| 銷貨成本 | 4231 USD | — | — | — | — |
| 毛利 | 1.76萬 USD | — | — | 23.33萬 USD | 63.8萬 USD |
| 研究與開發 | 208.66萬 USD | 49.27萬 USD | 95.48萬 USD | 94.28萬 USD | 144.77萬 USD |
| 銷售、一般及管理費用 | 683.97萬 USD | 259.86萬 USD | 291.6萬 USD | 272.29萬 USD | 309.74萬 USD |
| 營業費用 | 892.63萬 USD | 309.13萬 USD | 387.08萬 USD | 366.57萬 USD | 454.51萬 USD |
| 利息收入 | — | 5557 USD | 482 USD | 617 USD | 132 USD |
| 利息支出 | 6.6萬 USD | 24.84萬 USD | 21.87萬 USD | 74.09萬 USD | 11.4萬 USD |
| 營業利益 | −890.87萬 USD | −309.13萬 USD | −387.08萬 USD | −343.24萬 USD | −390.71萬 USD |
| 淨利 | −864.49萬 USD | −243.96萬 USD | −478.37萬 USD | −495.76萬 USD | −437.94萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
